E 955 (Sucralose)

Hinter der E-Nummer "E 955" versteckt sich der Süssstoff Sucralose.
Dieser Süssstoff ist 500- bis 600-mal süsser als Zucker und enthält keine Kalorien. In den USA ist Sucralose unter dem Markennamen Splenda bekannt und in über 3500 Lebensmitteln zu finden. In Deutschland findet man es unter dem Namen "Nevella". In der Schweiz ist Sucralose ebenfalls zugelassen. Man findet den Stoff zum Beispiel in Kaugummis, Eistee, Diät-Joghurt, Fruchtsaft und Zahnpasta.
Basis für die Herstellung von Sucralose normaler Zucker. Bei der chemischen Herstellung wird er mit Chlor versehen. So entsteht eine organische Chlorverbindung - eine Stoffklasse, die für ihre Giftigkeit bekannt ist, sagen Kritiker. Einige Vertreter dieser Stoffklasse haben in der Vergangenheit Schlagzeilen gemacht, etwa die Unkrautvernichter DDT und Lindan. Zudem gibt es eine ernst zu nehmende Studie über negative Nebenwirkungen vom Department of Pharmacology, Duke University Medical Center, Durham, North Carolina 27708, USA*.

Aus diesem Grunde verwenden wir kein E 955 in Edis Five Flowers Bachblüten Kaugummis, Pastillen oder sonstigen Edis Produkte.

SUNASAR AG

*Abstract: Splenda is comprised of the high-potency artificial sweetener sucralose (1.1%) and the fillers maltodextrin and glucose. Splenda was administered by oral gavage at 100, 300, 500, or 1000 mg/kg to male Sprague-Dawley rats for 12-wk, during which fecal samples were collected weekly for bacterial analysis and measurement of fecal pH. After 12-wk, half of the animals from each treatment group were sacrificed to determine the intestinal expression of the membrane efflux transporter P-glycoprotein (P-gp) and the cytochrome P-450 (CYP) metabolism system by Western blot. The remaining animals were allowed to recover for an additional 12-wk, and further assessments of fecal microflora, fecal pH, and expression of P-gp and CYP were determined. At the end of the 12-wk treatment period, the numbers of total anaerobes, bifidobacteria, lactobacilli, Bacteroides, clostridia, and total aerobic bacteria were significantly decreased; however, there was no significant treatment effect on enterobacteria. Splenda also increased fecal pH and enhanced the expression of P-gp by 2.43-fold, CYP3A4 by 2.51-fold, and CYP2D1 by 3.49-fold. Following the 12-wk recovery period, only the total anaerobes and bifidobacteria remained significantly depressed, whereas pH values, P-gp, and CYP3A4 and CYP2D1 remained elevated. These changes occurred at Splenda dosages that contained sucralose at 1.1-11 mg/kg (the US FDA Acceptable Daily Intake for sucralose is 5 mg/kg). Evidence indicates that a 12-wk administration of Splenda exerted numerous adverse effects, including (1) reduction in beneficial fecal microflora, (2) increased fecal pH, and (3) enhanced expression levels of P-gp, CYP3A4, and CYP2D1, which are known to limit the bioavailability of orally administered drugs.